At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 131 enrolled

Drug / intervention

LiRIS® +1 morecombination

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02411110

NCT02411110Phase 2Completed

Compare CT.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis/Bladder Pain Syndrome

Allergan·interventional·Posted Apr 8, 2015·Updated Jan 4, 2018

In Brief

A Phase 2 clinical trial evaluating LiRIS® and LiRIS Placebo for Cystitis, Interstitial and Painful Bladder Syndrome. Completed, enrolled 131 participants across 34 sites in 2 countries.

Detailed Summary

This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCystitis, Interstitial, Painful Bladder Syndrome

CountriesCanada, United States

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

First PostedApr 2015

Enrollment StartMay 2015

Primary CompletionOct 2016

Study CompletionJan 2017

TodayJul 2026

First PostedApr 8, 2015

Enrollment StartMay 21, 2015

Primary CompletionOct 12, 2016

Study CompletionJan 9, 2017

TodayJul 2, 2026

Enrollment to primary: 1.4 yearsPosted 11.2 years ago

Interventions

LiRIS®combination

LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.

LiRIS Placebocombination

LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.